Clinically meaningful MG-ADL response (≥2-point reduction) occurred in 69% of treated patients, exceeding the 53% response ...

The Value Operator is an orchestrator who centrally owns contract translation, governance, data configuration, and ...

Enrollment occurred across two Dallas hospitals; exclusions included transplant, LVAD, inotropes at discharge, existing meal ...

Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and ...

Microsimulation comparing three mt-sDNA rounds versus one colonoscopy over 10 years incorporated real-world adherence, test ...

Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...

In this episode of Managed Care Cast, Ella Hohmann speaks with Douglas Marks, MD, breast medical oncologist and associate ...

Ectopic germinal centers (GCs) were found to be a prognostic factor for poor outcomes for patients with thymoma-associated ...

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and ...

Across tumor types, 1-year NGS uptake rose substantially from 2018 to 2022, reaching 74.5% in aNSCLC and 78.1% in mCRC, but ...

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long ...